Hyundai Motor Shares Jump 15% on Possible Nvidia Tieup
By Reuters | 06 Jan, 2026
A possible Nvidia investment in Hyundai's robotics venture is thought to have been discussed between Hyundai Motor chairman Euisun Chung and Nvidia CEO Jensen Huang at CES.
Shares of Hyundai Motor rallied on Wednesday by as much as 14.9% to hit a record high in morning trade, outperforming the benchmark KOSPI's 1.2% gain amid market speculation about a potential deeper tie-up with Nvidia.
Shin Yoon-chul, an analyst at Kiwoom Securities, said Hyundai's announcement about the planned deployment in its factories of Atlas humanoid robots, made at the Consumer Electronics Show in Las Vegas, was insufficient to fully explain the rally. He noted that robot production is planned at around 30,000 units by 2028 and that the Atlas product was showcased only as a static mock-up display.
However, he said investor expectations appeared to be rising that Hyundai Motor Group's partnership with Nvidia could extend beyond a simple chip supply relationship, following a meeting between Hyundai Motor Group Chair Euisun Chung and Nvidia CEO Jensen Huang at CES.
Shin said the market seemed to be pricing in the possibility that Nvidia could deepen ties with the Hyundai Motor Group, including by making investments in Hyundai affiliates, which could leave further upside room in the shares of Hyundai Motor and its affiliates.
(Reporting by Jihoon Lee and Heekyong YangEditing by Ed Davies)
Recent Articles
- Become an AI Bonus Baby—or Just Get Paid Like One
- Ferrari Denies Requiring Luce EV Purchase to Access to Limited Edition Models
- SpaceX Turns to Bond Sale to Fatten $100.8 Billion Cash Stash
- Google DeepMind Signs AI Research Deal with Film Studio A24
- China's 618 Shopping Festival Sees Flat E-Commerce Sales from Cautious Shoppers
- Amazon Prime Day to Gauge US Consumer Strain as Focus Shifts to Basics
- China Closing in but US Still Leads in Biotech Innovation
- EV Surge Likely to Cut Oil Demand by Late 2027
- Kunal Shah tapped to Lead Meta's WhatsApp
- AbbVie Bets $10.9 Billion on Apogee in Next-Generation Immunology Growth Push
